#Pharma #Q3FY22 Earnings in Jan'22

Aggr.:
Revenue:~30.9K cr,+9%YoY
GP Margin: ~65%, -36bps YoY
EBITDA: ~7.5K cr, +4% YoY,
EBITDAMargin: ~24%, -108bps YoY
PAT:~4.8K cr, -9%QoQ, +4%YoY

Highest YoY:
Revenue, GPMargin & PAT growth: Supriya LifeSciences